Technical analysis of Opus Genetics, Inc. (IRD): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation).
Price Performance
| 1 month | +46.61% |
| 3 months | +32.92% |
| Year-to-date | +169.15% |
| 1 year | +278.32% |
52-Week Range
| 52-week High | $7.07 |
| 52-week Low | $1.35 |
| Avg Volume (90d) | 1.8M |
Technical Indicators
| SMA 50 | $3.98 |
| SMA 200 | $3.82 |
| Beta | 0.52 |
| 30-day Volatility (annualised) | 108.4% |
| Price vs SMA 50 | +35.8% |
| Price vs SMA 200 | +41.5% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $2.30 | |
| 2025-11 | $2.13 | -7.4% |
| 2025-12 | $2.01 | -5.6% |
| 2026-01 | $2.31 | +14.9% |
| 2026-02 | $4.16 | +80.1% |
| 2026-03 | $4.55 | +9.4% |
| 2026-04 | $5.11 | +12.3% |
| 2026-05 | $4.36 | -14.7% |
| 2026-06 | $4.11 | -5.7% |
| 2026-07 | $3.71 | -9.7% |
| 2026-08 | $3.62 | -2.4% |
| 2026-09 | $5.41 | +49.4% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-15 | | |
| 2026-09-15 | $-0.02 | |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | |
Price
| Price | $5.41 |
| Market Cap | $447M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -40.38 |
| EV / EBITDA | -3.16 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | -2.69 |
| Current Ratio | 12.19 |